Next-Generation Triple Agonist and Novel Obesity Treatments to Be Presented at ADA 2025
Hanmi Pharmaceutical announced on June 10 that it will participate in the American Diabetes Association (ADA 2025) and present its innovative research achievements in the field of obesity treatments.
Hanmi Pharmaceutical will attend ADA 2025, which will be held in Chicago, United States, from June 20 to June 23. The company plans to present preclinical and clinical research results for its "next-generation triple agonist for obesity treatment (LA-GLP/GIP/GCG, HM15275)" and "novel obesity treatment (LA-UCN2, HM17321)."
The research results to be presented include a total of six items: ▲Phase 1 clinical results of HM15275 ▲the potent weight loss efficacy and mechanism of action of HM15275 in obese animal models ▲the mechanism by which HM15275 improves the quality of weight loss compared to tirzepatide (Zepbound) ▲the weight loss and differentiated body composition improvement effects of HM17321 ▲the blood glucose control improvement effects of HM17321 ▲the synergistic effect on body composition improvement when HM15275 and HM17321 are used in combination.
In particular, the Phase 1 clinical results of HM15275 will be presented for the first time at ADA 2025. HM15275 and HM17321 are next-generation pipeline candidates following the innovation of "efeglenatide," which is targeted for commercialization in the second half of next year. Each is considered to have the potential to be developed as a "Best-in-Class" and "First-in-Class" new drug in the field of obesity treatment, respectively.
Currently, Hanmi Pharmaceutical is accelerating the development of next-generation obesity drugs with the goal of providing "patient-tailored solutions" throughout the entire cycle of obesity treatment. The company aims to secure a number of differentiated new drug candidates that address the limitations of existing obesity treatments by precisely reflecting the diverse characteristics and treatment needs of a broad range of obese patients.
Choi Inyoung, Head of Hanmi Pharmaceutical's R&D Center, stated, "This ADA 2025 will serve as an important stage to demonstrate Hanmi's research capabilities and global competitiveness in innovative drugs for metabolic and endocrine diseases, which we have accumulated over many years. Hanmi will strive to become a 'global frontier' leading the paradigm of obesity treatment worldwide, not only by introducing new mechanisms of action that surpass the limitations of existing obesity treatments, but also through differentiated development strategies. We will mobilize our full capabilities to achieve the fastest possible commercialization of new obesity drugs."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
